N-acetylcysteine for Alzheimer's Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Alzheimer's DiseaseN-acetylcysteine - DietarySupplement
Eligibility
55 - 85
All Sexes
What conditions do you have?
Select

Study Summary

This trial will investigate whether supplementing glycine and N-acetylcysteine can help improve cognitive decline in Alzheimer's disease.

Eligible Conditions
  • Alzheimer's Disease

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 9 Secondary · Reporting Duration: Day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation

Day 0
Activities of daily living
Damage due to oxidative stress
Endothelial dysfunction
Inflammatory cytokines
Mitochondrial energetics
Mitochondrial fuel oxidation
Oxidative stress
Plasma concentration of Brain-derived neurotropic factor (BDNF)
Cysteine
Day 0
Cognition
Done before supplementation and 24-weeks after starting supplementation
Brain glucose uptake
Brain inflammation

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Glycine plus N-acetylcysteine
1 of 2
Alanine
1 of 2

Experimental Treatment

Non-Treatment Group

52 Total Participants · 2 Treatment Groups

Primary Treatment: N-acetylcysteine · Has Placebo Group · Phase < 1

Glycine plus N-acetylcysteineExperimental Group · 2 Interventions: Glycine, N-acetylcysteine · Intervention Types: DietarySupplement, DietarySupplement
Alanine
DietarySupplement
PlaceboComparator Group · 1 Intervention: Alanine · Intervention Types: DietarySupplement
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Glycine
2012
Completed Phase 3
~30
N-acetylcysteine
2008
Completed Phase 4
~1290

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: day 0 of supplementation, 12-weeks and 24-weeks after starting supplementation

Who is running the clinical trial?

The Methodist Hospital Research InstituteOTHER
240 Previous Clinical Trials
35,559 Total Patients Enrolled
Baylor College of MedicineLead Sponsor
923 Previous Clinical Trials
5,987,997 Total Patients Enrolled
Rajagopal V Sekhar, M.D.Principal InvestigatorBaylor College of Medicine

Eligibility Criteria

Age 55 - 85 · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
The person has been gradually losing memory for over a year, with their Montreal Cognitive Assessment score being 10-20.
You have a study partner.\n